tivantinib Articles
ArQule and Daiichi Sankyo drop tivantinib trial in NSCLC
3 October 2012
Kyowa Hakko Kirin starts Ph III trial of ARQ 197 (tivantinib) in NSCLC patients in Asia
10 August 2011
Showing 1-4 of 4 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
